Soleus Capital Management has significantly expanded its investment in Celcuity, acquiring 629,398 additional shares that bring its total stake to over 1.8 million shares. The position, now valued at $180.36 million, represents 6.7% of the asset manager's total assets under management, establishing Celcuity as its third-largest holding.
The increased investment reflects substantial capital commitment to the clinical-stage biotechnology company. Celcuity's equity has appreciated considerably, with shares gaining 745% over the past twelve months, indicating strong market momentum for the company's development pipeline and research initiatives.
Soleus's expanded position underscores growing institutional confidence in Celcuity's potential, though the company remains in the clinical development phase. The move adds to recent investment activity in the biotech sector, where investors continue to deploy capital toward therapeutic development companies showing clinical promise.